Technology OverviewHµREL® Corporation provides proprietary co-cultures and patented microfluidic devices that elevate the cellular responsiveness, metabolic competency, and endurance of cells cultured in vitro, and that simulate pharmacokinetic interactions among multiple tissues and organs. These proprietary capabilities produce unrivaled levels of physiologically relevant predictive sensitivity—”human relevance”—that define the current state of the art of hepatic and multi-tissue cell-based assays.
HµREL®‘s technology is adaptible to numerous experimental applications, and compatible with virtually any type
U.S. Patent No’s. 5,612,188; 7,288,405; 8,030,061; other patents pending
of traditional in vitro assay modality (mass spectroscopic, immunohistochemical, immunofluorescent, gene expression, and others). Embodied in standard, micro-titer array format, HµREL®s are intended for “plug-and-play” compatibility with plate readers and other standard laboratory instruments, and their use can be automated for high throughput.
A patented HµREL® microfluidic “biochip” comprises an arrangement of separate but fluidically interconnected “organ” or “tissue” compartments. Each compartment contains a culture of living cells drawn from, or engineered to mimic primary function(s) of, the respective organ or tissue of a living animal. Microfluidic channels permit a culture medium that serves as a “blood surrogate” to re-circulate as in a living system, driven by a microfluidic pump. The geometry and fluidics of the device are fashioned to simulate the values of certain related physiological parameters found in the living creature.
Drug candidates or other substrates of interest are added to the culture medium and allowed to re-circulate through the device. The effects of drug compounds and their metabolites on the cells within each respective organ compartment are detected by measuring or monitoring key physiological events. The cell types employed may be derived from either standard cell culture lines or primary tissues.
Eric Novik, PhD
Mark Warren, OptiviaCholestasis: An Integrated Approach